Dacomitinib (PF299804) CAS 1110813-31-4

Basic Info

Model No.:  CAS 1110813-31-4

Additional Info

Packaging: 10g 100g 1kg

Productivity: 100 kg/month

Brand: cy

Transportation: Ocean,Land,Air

Place of Origin: China

Supply Ability: 50kg

Certificate: ISO 9001, GMP

Port: QINGDAO,SHANGHAI

Product Description

Dacomitinib package insert

Dacomitinib is an orally bioavailable, highly selective, second-generation small-molecule inhibitor of the pan-epidermal growth factor receptor (EGFR) family of tyrosine kinases (ErbB family) with potential antineoplastic activity. Dacomitinib specifically and irreversibly binds to and inhibits human EGFR subtypes, resulting in inhibition of proliferation and induction of apoptosis in EGFR-expressing tumor cells. EGFRs play major roles in tumor cell proliferation and tumor vascularization, and are often overexpressed or mutated in various tumor cell types.

dacomitinib mechanism of action

Dacomitinib is a selective and irreversible inhibitor of EGFR. It is a drug candidate for the treatment of non-small cell lung carcinoma. It is current under the Phase III clinical trials. It also shows potential for the treatment of HER-2 amplified breast cancer cells lines that are resistant to trastuzumab and lapatinib. 

dacomitinib fda approval

Dacomitinib is taken orally once-daily. It is an irreversible inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases. Dacomitinib targets multiple receptors of the HER pathway, whereas currently marketed HER-1 (EGFR) inhibitors for non-small cell lung cancer (NSCLC) target only one receptor in this pathway,developed by Pfizer.

Product Name	Dacomitinib
Synonyms	PF-299804 (Dacomitinib,PF-00299804);PF299804, PF299);Dacomitinib;PF-00299804-03;PF-00299804;DacoMitinib (PF-00299804);DacoMitinib,PF299804;DacoMitinib (PF299804,PF-00299804)
CAS	1110813-31-4
MF	C24H25ClFN5O2
MW	469.9390032
EINECS	N/A
Product Categories	-;Anti-cancer&immunity;Inhibitors
Mol File	1110813-31-4.mol